<menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • Your Good Partner in Biology Research

    Human B-cell leukemia/lymphoma 6,Bcl6 ELISA Kit

    • 中文名稱:
      人B細胞淋巴瘤因子6(Bcl6)ELISA Kit
    • 貨號:
      CSB-E14975h
    • 規格:
      96T/48T
    • 價格:
      ¥3600/¥2500
    • 其他:

    產品詳情

    • 產品描述:

      This Human BCL6 ELISA Kit was designed for the quantitative measurement of Human BCL6 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 18.75 pg/mL-1200 pg/mL and the sensitivity is 4.68 pg/mL.

    • 別名:
      B cell CLL/lymphoma 6 ELISA Kit; B cell lymphoma 6 protein ELISA Kit; B-cell lymphoma 5 protein ELISA Kit; B-cell lymphoma 6 protein ELISA Kit; BCL 5 ELISA Kit; Bcl 6 ELISA Kit; BCL-5 ELISA Kit; BCL-6 ELISA Kit; BCL5 ELISA Kit; BCL6 ELISA Kit; BCL6_HUMAN ELISA Kit; BCL6A ELISA Kit; cys his2 zinc finger transcription factor ELISA Kit; cys-his2 zinc finger transcription factor ELISA Kit; LAZ 3 ELISA Kit; LAZ 3 protein ELISA Kit; LAZ3 ELISA Kit; Lymphoma Associated Zinc Finger Gene On Chromosome 3 (LAZ3) ELISA Kit; Lymphoma associated zinc finger gene on chromosome 3 ELISA Kit; Protein LAZ-3 ELISA Kit; ZBTB 27 ELISA Kit; ZBTB27 ELISA Kit; Zinc finger and BTB domain containing protein 27 ELISA Kit; Zinc finger and BTB domain-containing protein 27 (ZBTB27) ELISA Kit; Zinc finger and BTB domain-containing protein 27 ELISA Kit; Zinc Finger Protein 51 (ZNF51) ELISA Kit; Zinc finger protein 51 ELISA Kit; zinc finger transcription factor BCL6S ELISA Kit; ZNF 51 ELISA Kit; ZNF51 ELISA Kit
    • 縮寫:
      BCL6
    • Uniprot No.:
    • 種屬:
      Homo sapiens (Human)
    • 樣本類型:
      serum, plasma, tissue homogenates
    • 檢測范圍:
      18.75 pg/mL-1200 pg/mL
    • 靈敏度:
      4.68 pg/mL
    • 反應時間:
      1-5h
    • 樣本體積:
      50-100ul
    • 檢測波長:
      450 nm
    • 研究領域:
      Epigenetics and Nuclear Signaling
    • 測定原理:
      quantitative
    • 測定方法:
      Sandwich
    • 說明書:
    • 精密度:
      Intra-assay Precision (Precision within an assay): CV%<8%
      Three samples of known concentration were tested twenty times on one plate to assess.
      Inter-assay Precision (Precision between assays): CV%<10%
      Three samples of known concentration were tested in twenty assays to assess.
    • 線性度:
      To assess the linearity of the assay, samples were spiked with high concentrations of human Bcl6 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
        Sample Serum(n=4)
      1:1 Average % 98
      Range % 94-103
      1:2 Average % 100
      Range % 97-104
      1:4 Average % 86
      Range % 83-89
      1:8 Average % 98
      Range % 94-103
    • 回收率:
      The recovery of human Bcl6 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
      Sample Type Average % Recovery Range
      Serum (n=5) 85 81-89
      EDTA plasma (n=4) 87 83-90
    • 標準曲線:
      These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
      pg/ml OD1 OD2 Average Corrected
      1200 2.790 2.701 2.746 2.588
      600 2.158 2.032 2.095 1.937
      300 1.269 1.304 1.287 1.129
      150 0.784 0.811 0.798 0.640
      75 0.516 0.531 0.524 0.366
      37.5 0.342 0.336 0.339 0.181
      18.75 0.246 0.252 0.249 0.091
      0 0.157 0.159 0.158  
    • 數據處理:
    • 貨期:
      3-5 working days

    產品評價

    靶點詳情

    • 功能:
      Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation.
    • 基因功能參考文獻:
      1. our exploratory study suggests that EOMES, BCL6 and GZMB gene expression are aberrant within the PB T cell transcriptome of HT patients. The association of this transcription signature with the heterogeneity of HT and disease control is suggested. PMID: 29319368
      2. Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas PMID: 28665415
      3. BCL6 overexpression in SHR reduced blood pressure, NLRP3 expression and inflammation in the renal cortex of SHR PMID: 29072703
      4. Although BCL6 controls follicular helper T cells activity in humans and mice, the role of miR-31 is restricted to human follicular helper T cell differentiation, reflecting a species specificity of the miR-31 action. PMID: 29133396
      5. Aberrant CD10 and BCL6 expression defines a subset of MCLs with higher mean Ki-67 index and higher prevalence of MUM1 expression PMID: 28628241
      6. BCL6 is a growth promoting factor in glioblastoma and glioma. PMID: 28356518
      7. IFN gamma induced upregulation of BCL6 was dependent on the classical STAT1 signaling pathway, and affected both major BCL6 variants. Interestingly, although IFN alpha induced stronger STAT1 phosphorylation than IFN gamma, it only slightly upregulated BCL6 in multiple myeloma lines. PMID: 29510136
      8. Findings demonstrate that BCL6 expression is downregulated by miR-519d which targets its 3 '-UTR. Also, BCL6 mediates the repression of miR-519d on cell proliferation and invasive capability of gastric cancer cells. PMID: 29510377
      9. In Pakistani population, the frequency of GCB type DLBCL [diffuse large B cell lymphoma ]expressing CD10 and BCL6 is 37.5%, and non- GCB type DLBCL [diffuse large B cell lymphoma ] expressing MUM1 is 62.5%. PMID: 29056123
      10. BCOR internal tandem duplication and/or nuclear immunoreactivity for BCOR or BCL6 can aid in the diagnosis of primitive myxoid mesenchymal tumor of infancy and help to differentiate it from congenital infantile fibrosarcoma. PMID: 28256570
      11. our findings provide a novel apoptotic regulatory pathway in which LITAF, as a transcription factor, inhibits the expression of BCL6, which leads to activation of the intrinsic mitochondrial pathway and tumor apoptosis. PMID: 27764808
      12. Ikaros regulates expression of the BCL6/BACH2 axis in acute lymphoblastic leukemia cells. PMID: 28030830
      13. our work casts new light on the biology of mantle cell lymphoma (MCL), revealing the role of SOX11 exerting a functional effect through the repression of BCL6 transcription in MCL cells PMID: 26710884
      14. BCL6 inhibitors have been shown to exert potent effects against these tumor types. Moreover, mechanism-based combinations of BCL6 inhibitors with other agents have yielded synergistic and often quite dramatic activity. Hence, there is a compelling case to accelerate the development of BCL6-targeted therapies for translation to the clinical setting PMID: 27881582
      15. High BCL6 expression is associated with good response to chemotherapy in acute lymphoblastic leukemia. PMID: 27015556
      16. BCL6 expression is present in isolated cortical neurons, granule cells in the cerebellum, scattered glial cells, and in some cells of the ependyma and choroid plexus. PMID: 26862951
      17. We show that human follicular lymphomas are dependent on BCL6 PMID: 28232365
      18. Aberrant BCL6 expression was strongly associated with poor reproductive outcomes in IVF cycles in women with unexplained infertility. PMID: 29126613
      19. EBNA3C inhibits the transcriptional activity of the Bcl6 promoter through interaction with the cellular protein IRF4. PMID: 28738086
      20. Data suggest that B-cell CLL/lymphoma 6 is a promising candidate as a single diagnostic biomarker for detection of endometriosis in women with otherwise unexplained infertility and may be associated with endometrial dysfunction, including progesterone resistance. PMID: 27222232
      21. The aim of this study was to investigate the clinical significance of three immune cell-related transcription factors, T-bet, GATA-3 and Bcl-6 in bladder cancer in Tunisian patients. PMID: 27237631
      22. analysis of role of BCL6 in maintaining activated B cell diffuse large B cell lymphoma reveals that ABC-DLBCL is a BCL6-dependent disease that can be targeted by rationally designed inhibitors that exceed the binding affinity of natural BCL6 ligands PMID: 27482887
      23. Results provide evidence that BCL6 overexpression is involved in genomic instability in multiple myeloma cells. PMID: 28544233
      24. Our data reveal a regulatory role of BCL6 in inhibiting antiviral resistance factors in follicular Th cells PMID: 28550121
      25. the high expressions of BCL6 and Lewis y antigen are associated with development, high tumor burden, and worse prognosis of ovarian cancer and targeting BCL6 could be a novel therapeutic strategy for ovarian cancer treatment. PMID: 28671040
      26. both mouse and human B cells, IFN-gamma synergized with B cell receptor, toll-like receptor, and/or CD40 activation signals to promote cell-intrinsic expression of the GC master transcription factor, B cell lymphoma 6 protein. PMID: 27069113
      27. MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer PMID: 27186677
      28. miR-10a directly recognizes the 3'-UTR of the BCL6 transcript and regulated BCL6 expression. PMID: 27815824
      29. This work identified BCL6 as a novel biomarker for early prediction of cerebral palsy. PMID: 28315684
      30. Bcl-6 expression in circulating follicular helper-like T cells may represent a reliable marker for the disease activity in systemic lupus erythematosus PMID: 27818202
      31. In addition, subsequent single-crystal X-ray diffraction analysis of F1324/BCL6(5-129) complex revealed that the high affinity of F1324 was caused by effective interaction of its side chains while its main chain structure was similar to that of BcoR(Arg498-514Pro). To our knowledge, F1324 is the strongest BCL6-binding peptide yet reported. PMID: 27856253
      32. We report the case of a 7-month-old girl with atypical oculo-facio-cardio-dental syndrome (OFCD). A novel de novo pathogenic mutation in the BCL6 interacting co-repressor gene (BCOR) (c.4540C>T; p.Arg1514*), was identified on the X chromosome PMID: 28317252
      33. JAK2 is a direct BCL6 target gene; BCL6 bound to the JAK2 promoter PMID: 27268052
      34. Deregulated BCL6 expression caused by hypermethylation and TET2 mutations may result in skewed follicular helper T cell differentiation and eventually contribute to angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma development in patients PMID: 27921272
      35. miR-339-5p inhibits migration and invasion in ovarian cancer by targeting NACC1 and BCL6. miR-339-5p may be a biomarker of metastasis in ovarian cancer; NACC1 had a predictive value for ovarian cancer progression PMID: 26553360
      36. Data show there was a positive correlation between B cell lymphoma 6 (Bcl-6) and B lymphocyte-induced maturation protein 1 (Blimp-1) at the level of mRNA. PMID: 27363279
      37. miR-155 overexpression plays a promoting role in the proliferative, migratory and invasive behavior of OSCC cells. Its effects on OSCC are possibly associated with its regulation of the BCL6/cyclin D2 axis. PMID: 26986233
      38. BCL6 Rearrangements are associated with Diffuse Large B-Cell Lymphoma. PMID: 26319027
      39. Bcl6, by interacting with the co-factors NcoR2 and HDAC3, plays a pivotal role in controlling IRF7 induction and antiviral signaling priming. PMID: 26728228
      40. diffuse large B-cell lymphoma patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis PMID: 26573234
      41. BCL6 promotes proliferation and survival of trophoblastic cells. PMID: 27029530
      42. Studies indicate that germinal centers (GC) B cells represent the normal counterpart of most B-cell lymphomas, which are often characterized by deregulated B cell lymphoma 6 (BCL6) expression or BCL6-mediated pathways. PMID: 26566802
      43. Bcl-6 mRNA and protein levels, as well as the frequencies of Bcl-6(+)CD4(+) cells were significantly increased in polyp tissues compared with normal controls. PMID: 25711734
      44. Follicular helper T cells differentiation is a multistage process involving BCL6 and other transcription factors, cytokines, and costimulation through ICOS and several other molecules. (Review) PMID: 26120879
      45. These results suggest that STAT6 plays an important role in regulating Sp1 and BCL6 through STAT2 to exert the anti-proliferative effects of type I IFN. PMID: 26945968
      46. Identified BCL6 to be a target of miR-10a in patients with Acute Myeloid Leukemia (AML). PMID: 26590574
      47. Study demonstrates that survivin belongs to the Tfh cell phenotype and ensures their optimal function by regulating transcriptional activity of Bcl-6. PMID: 26343374
      48. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. PMID: 21041953
      49. Taken together, our results demonstrated that miR-187-3p played a pivotal role on NSCLC through inhibiting cell proliferation, migration, invasion, and promoting apoptosis by targeting oncogenic BCL6. PMID: 26845350
      50. BCL6 gene expression is plays a role in the pathogenesis of diffuse large B-cell lymphoma. PMID: 26414904

      顯示更多

      收起更多

    • 相關疾?。?/div>
      Chromosomal aberrations involving BCL6 are a cause of B-cell non-Hodgkin lymphomas (B-cell NHL), including diffuse large B-cell lymphoma and follicular lymphoma. Approximately 40% of diffuse large B-cell lymphomas and 5 to 10% of follicular lymphomas are associated with chromosomal translocations that deregulate expression of BCL6 by juxtaposing heterologous promoters to the BCL6 coding domain. Translocation t(3;14)(q27;q32). Translocation t(3;22)(q27;q11) with immunoglobulin gene regions. Translocation t(3;7)(q27;p12) with IKZF1 gene 5'non-coding region. Translocation t(3;6)(q27;p21) with Histone H4. Translocation t(3;16)(q27;p11) with IL21R. Translocation t(3;13)(q27;q14) with LCP1.; DISEASE: Note=A chromosomal aberration involving BCL6 may be a cause of a form of B-cell leukemia. Translocation t(3;11)(q27;q23) with POU2AF1/OBF1.; DISEASE: Note=A chromosomal aberration involving BCL6 may be a cause of lymphoma. Translocation t(3;4)(q27;p11) with ARHH/TTF.
    • 亞細胞定位:
      Nucleus.
    • 組織特異性:
      Expressed in germinal center T- and B-cells and in primary immature dendritic cells.
    • 數據庫鏈接:

      HGNC: 1001

      OMIM: 109565

      KEGG: hsa:604

      STRING: 9606.ENSP00000232014

      UniGene: Hs.478588



    1v1周青梅郑宣木天寥
    <menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>
    <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>